Tabrizchi R, Lupichuk S M
Department of Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.
J Cardiovasc Pharmacol. 1995 Jul;26(1):137-44. doi: 10.1097/00005344-199507000-00022.
The effects of the nonpeptide angiotensin II receptor antagonist losartan and the angiotensin-converting enzyme inhibitor captopril on pressor responses to the selective alpha 1-adrenoceptor agonist cirazoline (10 ng/kg-3.0 mg/kg) in the pithed rat were compared. In addition, the effects of losartan and captopril on pressor responses to cirazoline were compared in the presence of the selective irreversible alpha 1-adrenoceptor antagonist SZL-49 (1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-bicyclo[2,2,2]octa-2,5- dienyl-carbonyl)-piperzine) and/or the Ca2+ channel antagonist nifedipine. Losartan (5.0 mg/kg) and captopril (3.0 mg/kg), as compared to saline, significantly lowered the blood pressure of intact, anaesthetized and pithed rats. Continuous infusion with vasopressin was used to restore the blood pressure of pithed rats pretreated with losartan or captopril to a level comparable to animals that had received saline. Losartan, captopril, nifedipine (1.0 mg/kg), and SZL-49 (10.0 mg/kg) antagonized the pressor actions of cirazoline, which displaced the dose-diastolic blood pressure response curve for the agonist to the right. Moreover, pressor responses to cirazoline were significantly reduced in rats that had received losartan and nifedipine in comparison to nifedipine alone. In contrast, in rats treated with nifedipine, further administration of captopril did not significantly reduce pressor responses to cirazoline as compared to nifedipine alone. Cirazoline-mediated pressor responses at all doses were significantly attenuated in rats treated with SZL-49 and either losartan or nifedipine combined as compared to SZL-49 alone. In contrast, only cirazoline-mediated pressor responses at lower doses were significantly reduced by pretreatment with a combination of SZL-49 and captopril as compared to SZL-49 alone.(ABSTRACT TRUNCATED AT 250 WORDS)
比较了非肽类血管紧张素II受体拮抗剂氯沙坦和血管紧张素转换酶抑制剂卡托普利对脊髓毁损大鼠对选择性α1肾上腺素能受体激动剂西拉唑啉(10 ng/kg - 3.0 mg/kg)升压反应的影响。此外,还比较了在选择性不可逆α1肾上腺素能受体拮抗剂SZL - 49(1 - (4 - 氨基 - 6,7 - 二甲氧基 - 2 - 喹唑啉基) - 4 - (2 - 双环[2,2,2]辛 - 2,5 - 二烯基 - 羰基) - 哌嗪)和/或钙通道拮抗剂硝苯地平存在的情况下,氯沙坦和卡托普利对西拉唑啉升压反应的影响。与生理盐水相比,氯沙坦(5.0 mg/kg)和卡托普利(3.0 mg/kg)能显著降低完整、麻醉和脊髓毁损大鼠的血压。持续输注血管加压素可将预先用氯沙坦或卡托普利处理的脊髓毁损大鼠的血压恢复到与接受生理盐水的动物相当的水平。氯沙坦、卡托普利、硝苯地平(1.0 mg/kg)和SZL - 49(10.0 mg/kg)可拮抗西拉唑啉的升压作用,使激动剂的剂量 - 舒张压反应曲线右移。此外,与单独使用硝苯地平相比,接受氯沙坦和硝苯地平的大鼠对西拉唑啉的升压反应明显降低。相反,在用硝苯地平处理的大鼠中,与单独使用硝苯地平相比,进一步给予卡托普利并未显著降低对西拉唑啉的升压反应。与单独使用SZL - 49相比,用SZL - 49与氯沙坦或硝苯地平联合处理的大鼠在所有剂量下西拉唑啉介导的升压反应均显著减弱。相反,与单独使用SZL - 49相比,仅在较低剂量下,用SZL - 49与卡托普利联合预处理可显著降低西拉唑啉介导的升压反应。(摘要截短于250字)